KINNATE BIOPHARMA
Kinnate Biopharma develops precision oncology therapeutics to treat patients with genomically-defined cancers. Its mission is to expand the reach of targeted therapeutics by developing products for underserved populations. The company utilizes its deep expertise in structure-based drug discovery, translational research, and patient-driven precision medicine. Its programs include candidates in preclinical development for cancers that are driven by specific oncogenic alterations in either the BRAF kinase gene or in the FGFR2 and FGFR3 kinase genes.
KINNATE BIOPHARMA
Social Links:
Industry:
Biopharma Biotechnology Health Care Medical Therapeutics
Founded:
2018-01-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.kinnate.com
Total Employee:
51+
Status:
Active
Total Funding:
194.5 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Apple Mobile Web Clips Icon WordPress Domain Not Resolving Wordpress Plugins
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Vida Ventures
Vida Ventures investment in Series C - Kinnate Biopharma
Fidelity Management and Research Company
Fidelity Management and Research Company investment in Series C - Kinnate Biopharma
RA Capital Management
RA Capital Management investment in Series C - Kinnate Biopharma
Foresite Capital
Foresite Capital investment in Series C - Kinnate Biopharma
Leerink Partners
Leerink Partners investment in Series C - Kinnate Biopharma
Logos Capital
Logos Capital investment in Series C - Kinnate Biopharma
Venrock Healthcare Capital Partners
Venrock Healthcare Capital Partners investment in Series C - Kinnate Biopharma
Nextech Invest
Nextech Invest investment in Series C - Kinnate Biopharma
Boxer Capital
Boxer Capital investment in Series C - Kinnate Biopharma
OrbiMed
OrbiMed investment in Series C - Kinnate Biopharma
Key Employee Changes
| Date | New article |
|---|---|
| 2020-07-09 | Kinnate Adds WuXi NextCODE’s Richard Williams as Chief Medical Officer |
Official Site Inspections
http://www.kinnate.com Semrush global rank: 245.56 K Semrush visits lastest month: 284.97 K
- Host name: 23.98.198.104.bc.googleusercontent.com
- IP address: 104.198.98.23
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "Kinnate Biopharma"
Kinnate Biopharma - Crunchbase Company Profile
Kinnate Biopharma may be growing as evidenced by the company being the target of a tender offer and subsequent acquisition by XOMA Corporation. The acquisition agreement included a cash per share offer ranging from $2.3352 to …See details»
Corporate Profile | Kinnate Biopharma
Kinnate Biopharma Inc. is a clinical-stage precision oncology company focused on expanding on the promise of targeted therapies for those battling cancer. The company is developing …See details»
XOMA Enters into Agreement to Acquire Kinnate ... - XOMA …
EMERYVILLE, Calif., Feb. 16, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today it has entered an agreement to acquire Kinnate Biopharma Inc. …See details»
Kinnate Biopharma Inc. Enters into Agreement to be Acquired by …
Feb 16, 2024 SAN FRANCISCO and SAN DIEGO, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate” or the “Company”), a clinical-stage …See details»
Kinnate Biopharma Inc. - LinkedIn
Kinnate Biopharma Inc. is a clinical-stage precision oncology company focused on expanding on the promise of targeted therapies for those battling cancer.See details»
Kinnate Biopharma Inc. - AnnualReports.com
Kinnate Biopharma Inc. is a clinical-stage precision oncology company focused on expanding on the promise of targeted therapies for those battling cancer. The company is developing …See details»
Science & Pipeline - Kinnate Biopharma Inc.
Exarafenib (KIN-2787) is an orally administered, potent and selective investigational small molecule pan-RAF inhibitor. KN-8701 is an ongoing, global Phase 1 clinical trial …See details»
Kinnate Biopharma Inc. Provides Corporate Update and Highlights …
License to develop and commercialize Kinnate s currently most advanced kinase inhibitor candidates in Greater China. Expanded the organization to 61 full-time employees as of …See details»
Kinnate Biopharma - Funding, Financials, Valuation & Investors
Kinnate Biopharma is registered under the ticker NASDAQ:KNTE . Their stock opened with $20.00 in its Dec 2, 2020 IPO. Stock Symbol NASDAQ:KNTE ; Valuation at IPO $830.5M; …See details»
Kinnate Biopharma Company Profile - Office Locations ... - Craft
Kinnate Biopharma is a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. It utilizes …See details»
Kinnate Biopharma Inc. Announces Pipeline Updates, Strategic ...
Sep 18, 2023 Kinnate Biopharma Inc. Announces Pipeline Updates, Strategic Reprioritization and Workforce Restructuring Kinnate Biopharma Mon, Sep 18, 2023, 1:10 PM 12 min readSee details»
Kinnate Biopharma Inc. Announces Third Quarter 2022 Financial …
Sep 30, 2022 Expanded the organization to 86 full-time employees as of September 30, 2022, of which 64 were engaged in research and development activities. ... About Kinnate Biopharma …See details»
Nima Farzan of Kinnate Biopharma: Five Things You Need To Be A …
Sep 5, 2022 When your organization started, what was its vision, what was its purpose? Kinnate is a clinical-stage precision oncology company. Our purpose is to provide hope to those …See details»
Kinnate Biopharma Inc. Announces Second Quarter 2022 Financial …
Jun 30, 2022 Expanded the organization to 82 full-time employees as of June 30, 2022, of which 61 were engaged in research and development activities. ... Kinnate Biopharma Inc. …See details»
Kinnate Biopharma Inc. Announces Pipeline Updates,
Sep 18, 2023 Kinnate Biopharma Inc. is a clinical-stage precision oncology company founded with a mission to inspire hope in those battling cancer by expanding on the promise of targeted …See details»
Kinnate Biopharma Inc. Announces FDA Clearance of …
Jan 18, 2022 Planned initiation of Phase 1 clinical trial for KIN-3248 in 1H2022SAN FRANCISCO and SAN DIEGO, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma …See details»
Kinnate Biopharma: Righting The Ship, But Still Not The Right Time ...
Dec 12, 2023 Kinnate Biopharma is a developmental biotech specializing in discovery of anticancer targeted therapies, most notably a novel RAF inhibitor that may help overcome …See details»
Kinnate Biopharma Inc. Announces FDA Clearance of …
Jan 18, 2022 SAN FRANCISCO and SAN DIEGO, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused …See details»
Kinnate Biopharma Inc. Reports First Quarter 2021 Financial …
May 17, 2021 KIN-2787 is the company’s RAF inhibitor candidate for patients with mutant BRAF-driven solid tumors Planned initiation of Phase 1 clinical trial for KIN-2787 in mid-2021 …See details»
Kinnate Biopharma Inc. to Present Pre-Clinical Data from its RAF …
May 10, 2021 SAN FRANCISCO & SAN DIEGO--(BUSINESS WIRE)--May 10, 2021-- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the …See details»